Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Feb;51(2):393-401.
doi: 10.1128/JCM.02724-12. Epub 2012 Nov 14.

Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs

David J Horne  1 , Lancelot M Pinto, Matthew Arentz, S-Y Grace Lin, Edward Desmond, Laura L Flores, Karen R Steingart, Jessica Minion
Affiliations
Meta-Analysis

Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs

David J Horne et al. J Clin Microbiol. 2013 Feb.

Abstract

In an effort to update and clarify policies on tuberculosis drug susceptibility testing (DST), the World Health Organization (WHO) commissioned a systematic review evaluating WHO-endorsed diagnostic tests. We report the results of this systematic review and meta-analysis of the diagnostic accuracy and reproducibility of phenotypic DST for first-line and second-line antituberculosis drugs. This review provides support for recommended critical concentrations for isoniazid and rifampin in commercial broth-based systems. Further studies are needed to evaluate critical concentrations for ethambutol and streptomycin that accurately detect susceptibility to these drugs. Evidence is limited on the performance of DST for pyrazinamide and second-line drugs.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Flow of studies in the review. *, a total of 45 papers evaluated DST for first-line drugs, 12 for second-line drugs, and 51 for both first- and second-line drugs.
See this image and copyright information in PMC

References

    1. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. 2012. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull. World Health Organ. 90:111–119D - PMC - PubMed
    1. World Health Organization 2011. Guidelines for the programmatic management of drug-resistant tuberculosis—2011 update. World Health Organization, Geneva, Switzerland: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf Accessed 25 February 2012 - PubMed
    1. World Health Organization 2011. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2010.7. World Health Organization, Geneva, Switzerland: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf Accessed 25 February 2012
    1. World Health Organization 2008. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf Accessed 25 February 2012 - PubMed
    1. Kim SJ. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564–569 - PubMed

Publication types

MeSH terms

Substances